Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
AVXL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $142.75M
- EPS (TTM)
- -$0.14
- Dividend yield
- None
- 52-week range
- 1.50 – 9.95
- Day range
- 1.50 – 1.58
- Volume / Avg
- 1.47M / 970.76K
- Beta
- —
- Shares outstanding
- 92.70M
- Next earnings
- Nov 24, 2026
52-week range
AVXL stock today
On Oct 8, AVXL ended the session at $1.54, adding $0.01 (0.65%), versus the S&P 500's 0.47% decline. Shares are 84.5% below their 52-week high of $9.95 and 2.7% above the 52-week low of $1.50, near the bottom of the past year's range. AVXL is down 57.0% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 84.4%.
Anavex Life Sciences has posted a net loss over the last twelve months (EPS of -$0.14), so its P/E ratio is not meaningful. Anavex Life Sciences's next earnings report is expected on Nov 24, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Anavex Life Sciences
Company profileAnavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer .
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Terrie Kellmeyer Ph.D.
- Headquarters
- New York, NY
- Employees
- 34
- Website
- anavex.com
Analyst forecast
ForecastConsensus (1 analysts)
none
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 24, 2026
Anavex Life Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARMPArmata Pharmaceuticals Inc. | 3.86 | +1.31% | $143.52M | vs AVXL |
| MOLNMolecular Partners AG ADR | 3.81 | 0.00% | $145.94M | vs AVXL |
| VYGRVoyager Therapeutics Inc. | 2.37 | -4.05% | $146.03M | vs AVXL |
| OTLKOutlook Therapeutics Inc. | 0.564 | -4.41% | $137.30M | vs AVXL |
| ABOSAcumen Pharmaceuticals Inc. | 2.10 | 0.00% | $151.87M | vs AVXL |
| TARAProtara Therapeutics Inc. | 2.65 | +2.32% | $156.60M | vs AVXL |
| CRDLCardiol Therapeutics Inc. Class A | 1.30 | -1.52% | $157.97M | vs AVXL |
| TNYATenaya Therapeutics Inc. | 0.5442 | +2.02% | $122.03M | vs AVXL |
Indexes, lists and sector
Anavex Life Sciences stock FAQ
What is Anavex Life Sciences's stock price today?
AVXL last traded at $1.54 as of Oct 8, 4:00 PM EDT, up 0.65% on the day. Prices are delayed at least 15 minutes.
Does Anavex Life Sciences pay a dividend?
No. Anavex Life Sciences does not currently pay a regular cash dividend.
When is Anavex Life Sciences's next earnings date?
Anavex Life Sciences is expected to report earnings on Tuesday, November 24, 2026.
Who is Anavex Life Sciences's CEO?
Dr. Terrie Kellmeyer Ph.D. is the chief executive officer of Anavex Life Sciences Corp., which has about 34 employees.
Has AVXL ever split its stock?
Yes. The most recent AVXL stock split was a 1-for-4 split on Oct 7, 2015.
What is the AVXL 52-week high?
The 52-week high for AVXL is $9.95 and the 52-week low is $1.50. The stock is currently 84.5% below its high.